A
Alcista
Alcista · 25%CAPR
$14.03
Precio del escenario
$6.710
-0.517 (-7.70%)Al cierre
Loading chart…
- Máximo
- 7.250
- Apertura
- 7.210
- Precio medio ponderado por volumen
- 6.88
- Volumen
- 1.95M
- Capitalización
- 148.38M
- Mínimo
- 6.680
- Importe
- 13.45M
- EV/EBITDA, TTM
- 0.00
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
Análisis de IA of Capricor Therapeutics, Inc. (CAPR)
MantenerCapricor Therapeutics Inc is currently not a strong buy due to its high risk factors, despite some positive catalysts. The current price is $7.83, with a significant year-to-date decline of 72.34%. The RSI is at 35.586, indicating that the stock is oversold, but it also reflects a lack of momentum. The upcoming FDA decision on November 22 could be a major catalyst, but the market sentiment is cautious, with analysts predicting a potential drop in stock price. The main risk is the negative sentiment surrounding the FDA's likely response, which could lead to further declines.
Recomendaciones de analistas (1)
+668.55% de potencial alcista
Comprar
1 Comprar
0 Mantener
0 Vender
Actual: 6.71
Mínimo
45.00
Promedio
51.57
Máximo
60.00
H.C. Wainwright
Neutral
—
2026-10-05
H.C. Wainwright
2026-10-05
Precio objetivo
—
Neutral
Roth Capital
Neutral
$7
2026-10-05
Roth Capital
2026-10-05
Precio objetivo
$7
Neutral
B. Riley
Comprar
$21
2026-09-14
B. Riley
2026-09-14
Precio objetivo
$21
Comprar
Piper Sandler
Sobreponderar
$25
2026-09-01
Piper Sandler
2026-09-01
Precio objetivo
$25
Sobreponderar
Oppenheimer
Superar al mercado
$54
2026-08-25
Oppenheimer
2026-08-25
Precio objetivo
$54
Superar al mercado
Métricas de valoración
El PER previsto actual de Capricor Therapeutics, Inc. (CAPR) es 78.74, frente a su media de 5 años de 7.32.
Escenarios de precio de Alphio AI para CAPR
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con CAPR en cartera
Cronología de eventos
Noticias
9.010-08stocktwitsCapricor's Deramiocel Under FDA Review for Heart Indication
9.010-05stocktwitsCapricor's Therapy Significantly Slows Muscle Decline in DMD Patients
9.010-01stocktwitsCapricor's Deramiocel FDA Approval Decision Approaches
4.509-30NASDAQ.COMNASDAQ 100 Pre-Market Activity Overview
4.509-30stocktwitsInvestors Await PCE Inflation and GDP Data
Preguntas frecuentes sobre CAPR, respondidas por Alphio AI
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Capricor Therapeutics Inc is currently not a strong buy due to its high risk factors, despite some positive catalysts. The current price is $7.83, with a significant year-to-date decline of 72.34%. The RSI is at 35.586, indicating that the stock is oversold, but it also reflects a lack of momentum. The upcoming FDA decision on November 22 could be a major catalyst, but the market sentiment is cautious, with analysts predicting a potential drop in stock price. The main risk is the negative sentiment surrounding the FDA's likely response, which could lead to further declines.
1 analysts cover CAPR: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 51.57.
Comunidad
Más ↗
CAPR stock rose nearly 5% as Capricor presented heart data for Deramiocel ahead of the November FDA decision. $CAPR $XBI $VTI
Mostrar más
$CAPR is in focus at WMS 2026 today 👀🧬 Capricor will share 24-month Deramiocel data across muscle and cardiac outcomes. 📊❤️ 82 patients reached the 24-month time point, with 40 originally assigned to Deramiocel. 💪 The 24-month data were part of Capricor’s recent major BLA amendment. 🚀 With shares finishing 4.2% higher yesterday, let’s see if that strength continues today. 👀📊
Mostrar más$CAPR has a lot riding on the next Deramiocel update. 👀 The 24-month HOPE-3 data gives investors a longer look at the drug. 82 patients have now hit the two-year mark. 🧬 Upper-limb function remains the key focus after HOPE-3 met its primary endpoint. Nov. 22 is the date to watch. 👀 Meanwhile, you can find Capricor’s latest price target.
Mostrar más$CAPR fell 1.8% yesterday, but the bigger story may be what’s coming next. 👀 Capricor will unveil 24-month HOPE-3 data at WMS. 🧬 82 patients have now reached the 24-month mark, giving the study a longer-term look. 📊 Those analyses were also included in the recent Deramiocel BLA amendment. 📄 Meanwhile, take a look at CAPR’s latest price target here 👉
Mostrar másEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.